Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperventilation and Anesthesia in ECT for MDD
NCT02924090Phase 4Unknown
- Sponsor
- University of Manitoba
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ketamine in major depressive disorder (MDD) (4 arms), sponsored by University of Manitoba. Primary endpoints: EEG seizure duration at 3 months and ECT-induced seizure duration at 3 months. Status: unknown.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02924090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924090.